Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9vHPV-BCG for Cervical HPV Infection
NCT06959563Phase 1Active, not recruiting
- Start
- Apr 2025
- Primary completion
- Oct 2026
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of recombinant human papillomavirus 9-valent vaccine and bcg vaccine in human papillomavirus infection. Primary endpoints: HPV testing by standard PCR assay at 28 days, IGRA blood test with HPV protein antigen at 28 days and 1 more. Started Apr 2025; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccinebcg vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT06959563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06959563.